Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart +/- Anlotinib in Advanced Endometrial Cancer
NCT04574284Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in endometrial cancer (EC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Sep 2020; status: completed.
02
Drugs
benmelstobart
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04574284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04574284.